Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091695 | 0.83 | EPHX2 (0.32) | EPHX2 | |
| SCHEMBL2093875 | 0.82 | GPR3 (0.35) | EPHX2KIF11GPR3PIM1NOTUM | |
| SCHEMBL254957 | 0.80 | MAPT (0.56) | EPHX2MAPTKIF11KMT2AMEN1 | |
| SCHEMBL8142070 | 0.80 | CA2 (0.32) | — | |
| SCHEMBL2091933 | 0.79 | FFAR1 (0.40) | MAPTKIF11ALDH1A1ALOX15TSHR | |
| SCHEMBL2090987 | 0.77 | ACACB (0.38) | MAPTKIF11KMT2AMEN1CYP3A4 | |
| SCHEMBL513896 | 0.77 | CA1 (0.48) | EPHX2KIF11ALDH1A1TSHRTRPV1 | |
| SCHEMBL16188087 | 0.77 | MAPT (0.47) | EPHX2MAPTKIF11KMT2AMEN1 | |
| SCHEMBL97113 | 0.77 | EPHX2 (0.47) | EPHX2MAPTKIF11KMT2AMEN1 | |
| SCHEMBL2090940 | 0.74 | CA1 (0.33) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| EP-2719688-B1 | Process for producing tetrazolyloxime derivatives | NIPPON SODA CO (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2719686-B1 | Process to halogenate a picoline derivative | NIPPON SODA CO (JP) | 2015-12-02 | — | — | EP | disclosed |
| EP-2719687-B1 | Process to make a bromopicoline derivative | NIPPON SODA CO (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-9018385-B2 | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9012653-B2 | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-9000178-B2 | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8962848-B2 | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative | NIPPON SODA CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1862453-A1 | MONOMOLECULAR CONDUCTIVE COMPLEX, CONDUCTIVE SELF-ASSEMBLED FILM AND ASSEMBLY OF ELECTRODE COMPOSED OF METAL AND SEMICONDUCTOR MAKING USE OF THE SAME | Tokyo Institute of Technology (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5021412-A | Protecting agricultural crops | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0354297-A1 | Thiadiazines, process for production thereof, and insecticidal and acaricidal agents comprising the thiadiazines | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | EPHX2 3662/4885MAPT 4117/4885KIF11 3946/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | EPHX2 3472/4885MAPT 4299/4885KIF11 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.